Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Agnes Männik"'
Autor:
Branislava Raičević, Ivana Stević, Dragana Lakić, Agnes Männik, Kalina Gjorgjievska, Bojan Labachevski, Kristina Pavlovska, Miodrag Žunić, Petya Milushewa, Guenka Petrova, Dominik Grega, Przemysław Holko, Slobodan M. Janković
Publikováno v:
Biotechnology & Biotechnological Equipment, Vol 38, Iss 1 (2024)
Drugs for the treatment of obesity show significant effectiveness, but the adverse effects (ADRs) of these drugs are numerous and varied, and some of them are highly cost-generating. Our research aimed to define the health care utilization pattern in
Externí odkaz:
https://doaj.org/article/9a8dd63dcb3e4d0084a52f745cecb063
Autor:
Szczepan Jakubowski, Pawel Kawalec, Przemyslaw Holko, Iwona Kowalska-Bobko, Maria Kamusheva, Guenka Petrova, Pero Draganić, Leos Fuksa, Agnes Männik, Fanni Ispán, Vitalis Briedis, Ioana Bianchi, Marian Sorin Paveliu, Tomas Tesar
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Objectives: The aim of this study was to characterize the reimbursement policy for orphan drugs (ODs) in Central and Eastern European (CEE) countries in relation to the availability and impact of clinical evidence, health technology assessment (HTA)
Externí odkaz:
https://doaj.org/article/13de524ced3b41b7bff0b3ba11c5c87c
Autor:
Krzysztof Piotr Malinowski, Paweł Kawalec, Wojciech Trąbka, Christoph Sowada, Guenka Petrova, Manoela Manova, Alexandra Savova, Pero Draganić, Juraj Slabý, Agnes Männik, Kristóf Márky, Zinta Rugaja, Jolanta Gulbinovic, Tomas Tesar, Marian Sorin Paveliu
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 15, Iss 1, Pp 1-13 (2020)
Abstract Background The reimbursement of orphan drugs (OD) is an increasingly important for country policymakers, and still insufficiently understood, especially in Central and Eastern Europe. The aim of this research was to provide a comprehensive d
Externí odkaz:
https://doaj.org/article/3a15a73178a843488cbbf82641d08803
Autor:
Krzysztof Piotr Malinowski, Paweł Kawalec, Wojciech Trąbka, Marcin Czech, Guenka Petrova, Manoela Manova, Alexandra Savova, Pero Draganić, Lenka Vostalová, Juraj Slabý, Agnes Männik, Kristóf Márky, Zinta Rugaja, Jolanta Gulbinovic, Tomas Tesar, Marian Sorin Paveliu
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
BackgroundReimbursement policies influence access of patients to orphan drugs in the European countries.ObjectivesTo provide a comprehensive description of orphan drug reimbursement policies and to assess reimbursement decision-making process in the
Externí odkaz:
https://doaj.org/article/0060948c11e742faa55b2b79d100a3a7
Autor:
Maria Kamusheva, Manoela Manova, Alexandra T. Savova, Guenka I. Petrova, Konstantin Mitov, András Harsányi, Zoltán Kaló, Kristóf Márky, Pawel Kawalec, Bistra Angelovska, Dragana Lakić, Tomas Tesar, Pero Draganic, Mary Geitona, Magdalini Hatzikou, Marian S. Paveliu, Agnes Männik
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Objectives: The aim of the study was to compare the access of patients with rare diseases (RDs) to biotechnological drugs in several Central and Eastern European countries (CEECs). We focused on the legislative pricing and reimbursement requirements,
Externí odkaz:
https://doaj.org/article/be8ef423712946f5aac5134bb2ec1d6a
Autor:
Paweł Kawalec, Tomas Tesar, Lenka Vostalova, Pero Draganic, Manoela Manova, Alexandra Savova, Guenka Petrova, Zinta Rugaja, Agnes Männik, Christoph Sowada, Ewa Stawowczyk, Andras Harsanyi, Andras Inotai, Adina Turcu-Stiolica, Jolanta Gulbinovič, Andrzej Pilc
Publikováno v:
Frontiers in Pharmacology, Vol 8 (2017)
Objectives: The aim of this study was to review reimbursement environment as well as pricing and reimbursement requirements for drugs in selected Central and Eastern Europe (CEE) countries.Methods: A questionnaire-based survey was performed in the pe
Externí odkaz:
https://doaj.org/article/b0fa5d3837f14a2fbbb05e49a187068d
Autor:
Paweł Kawalec, Ewa Stawowczyk, Tomas Tesar, Jana Skoupa, Adina Turcu-Stiolica, Maria Dimitrova, Guenka I. Petrova, Zinta Rugaja, Agnes Männik, Andras Harsanyi, Pero Draganic
Publikováno v:
Frontiers in Pharmacology, Vol 8 (2017)
Objectives: The aim of this study was to review the requirements for the reimbursement of biosimilars and to compare the reimbursement status, market share, and reimbursement costs of biosimilars in selected Central and Eastern European (CEE) countri
Externí odkaz:
https://doaj.org/article/ce1342996d2647398a53000ed330f02b
Autor:
Wojciech Trąbka, Guenka Petrova, Manoela Manova, Christoph Sowada, Pero Draganić, Agnes Männik, Alexandra Savova, Krzysztof Piotr Malinowski, Kristóf Márky, Marian Sorin Paveliu, Tomas Tesar, Paweł Kawalec, Juraj Slabý, Zinta Rugaja, Jolanta Gulbinovič
Publikováno v:
Orphanet journal of rare diseases, London : BioMed Central, 2020, vol. 15, no. 1, art. no. 277, p. [1-13]
Orphanet Journal of Rare Diseases
Orphanet Journal of Rare Diseases, Vol 15, Iss 1, Pp 1-13 (2020)
Orphanet Journal of Rare Diseases
Orphanet Journal of Rare Diseases, Vol 15, Iss 1, Pp 1-13 (2020)
Background The reimbursement of orphan drugs (OD) is an increasingly important for country policymakers, and still insufficiently understood, especially in Central and Eastern Europe. The aim of this research was to provide a comprehensive descriptio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e500972dee9ea52912420e7fe38731d0
https://www.bib.irb.hr/1223202
https://www.bib.irb.hr/1223202
Publikováno v:
Value in Health. 18(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7710ef38de7b557698ebc5a56436426
Publikováno v:
Value in Health. 19:A610
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7d7847ba2a14a90ecfdf22584735091
https://doi.org/10.1016/j.jval.2016.09.1519
https://doi.org/10.1016/j.jval.2016.09.1519